HNF4A Thr130Ile

HNF4A Thr130Ile — A Hepatocyte Switch With Metabolic Consequences

HNF4A | Hepatocyte Nuclear Factor 4-Alpha: a master transcription factor that
controls hundreds of target genes in the liver, pancreatic beta cells, kidney,
and intestine. It sits at the apex of the MODY transcription factor cascade,
directly activating HNF1A expression.
The Thr130Ile variant (T130I) substitutes threonine for isoleucine at position
130 in the DNA-binding domain — a domain so conserved it is essentially identical
across vertebrates. The result is a partial, tissue-selective loss of
transcriptional activity that affects the liver more than the pancreas, tilting
the metabolic balance toward insulin resistance and dyslipidemia in T allele
carriers.

The Mechanism

The p.Thr130Ile substitution falls within the DNA-binding domain of HNF4A.
Zhu et al. 2003 | Zhu Q et al. T130I mutation in HNF-4alpha gene is a
loss-of-function mutation in hepatocytes and is associated with late-onset
Type 2 diabetes mellitus in Japanese subjects. Diabetologia, 2003
demonstrated that T130I retains normal transcriptional activity in HeLa cells
and MIN6 beta-cell-like cells, but shows 27–78% of wild-type activity in HepG2
hepatoma cells and primary cultured mouse hepatocytes. The functional impairment
is therefore hepatocyte-specific, not pancreatic — a key distinction from the
truly pathogenic MODY1 nonsense variants (e.g. rs137853334, p.Gln277Ter) that
ablate activity in all tissues.

In hepatocytes, HNF4A normally drives expression of genes controlling
[gluconeogenesis | the production of glucose from non-carbohydrate sources in
the fasting state], lipid metabolism (ApoAII, ApoB, ApoCI/II, CETP), and
bile acid synthesis. Partial loss of HNF4A activity in the liver disrupts
these programs, producing the clinical signature seen in T130I carriers:
elevated fasting glucose, insulin resistance, hypertriglyceridemia, and
reduced HDL-cholesterol.

The Evidence

The largest analysis of T130I and type 2 diabetes comes from a
meta-analysis by Jafar-Mohammadi et al. 2011 | Jafar-Mohammadi B et al.
A role for coding functional variants in HNF4A in type 2 diabetes
susceptibility. Diabetologia, 2011
combining data from 14,279 cases and 26,835 controls: OR 1.20 (95% CI 1.10–1.30),
p=2.1×10⁻⁵. This is a modest but well-replicated effect. The original Japanese
discovery cohort (Zhu 2003) found a larger OR of 4.3 in a smaller sample —
the larger meta-analytic OR of 1.20 is the more reliable estimate.

Population-specific effects are notable.
Granados-Silvestre et al. 2017 | Granados-Silvestre MA et al. Susceptibility
background for type 2 diabetes in eleven Mexican Indigenous populations:
HNF4A gene analysis. Mol Genet Genomics, 2017
found the T allele at 2.7–16% in Mexican indigenous groups, with a consistent
association with hypertriglyceridemia. The variant appears to have been
positively selected in some Amerindian populations, possibly conferring
metabolic advantage under historical nutritional stress while now contributing
to T2D risk in a calorie-dense environment.

A pediatric metabolic syndrome association was documented by
García-Rodríguez et al. 2020 | García-Rodríguez MH et al. Association of
the T130I Variant of the HNF4A Gene with Metabolic Syndrome and Its
Components in Mexican Children. Metab Syndr Relat Disord, 2020:
OR 2.31 (95% CI 1.10–4.83, p=0.026) for metabolic syndrome in children,
with abdominal obesity as the dominant component (OR 1.20). This is the
earliest age at which T130I phenotypic consequences have been documented.

The Spanish family study by Cieza-Borrella et al. 2014 | Cieza-Borrella C
et al. Early-onset type 2 diabetes mellitus is associated to HNF4A T130I
polymorphism in families of central Spain. J Investig Med, 2014
found that T130I carriers in diabetes families had significantly higher
HbA1c and fasting glucose than non-carriers, with diabetes onset often
triggered by stressful situations and tightly linked to gestational diabetes
in female carriers.

Practical Actions

The key implication for T allele carriers is liver-centric metabolic
monitoring: fasting lipid panel (particularly triglycerides and HDL),
fasting glucose, and HbA1c. The hepatocyte-specific nature of the
dysfunction means insulin secretion capacity is less impaired than in
full MODY1 patients, but liver-driven insulin resistance and dyslipidemia
accumulate over time. Reducing hepatic triglyceride burden — through
dietary carbohydrate restriction and omega-3 fatty acids — directly
addresses the HNF4A-driven lipid dysregulation pathway.

Homozygous TT carriers are extremely rare (~0.1%) and warrant additional
vigilance: both alleles carry the partial loss-of-function, potentially
doubling hepatic HNF4A impairment and compounding metabolic risk.

Interactions

HNF4A directly activates HNF1A transcription. Carriers who also have
functional variants in HNF1A (rs1169288, Ile27Leu) or HNF1B may have
compounded transcription factor cascade disruption. The T130I variant
in HNF4A affects the DNA-binding domain, while the truly pathogenic
MODY1 nonsense variants (rs137853334) eliminate transactivation entirely —
these are mechanistically distinct and should not be conflated in clinical
communication.